Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-guided Therapy in Newly Diagnosed PTCL (THEORY)
NCT05675813Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Feb 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor, azacitidine, duvelisib, tucidinostat, tislelizumab in peripheral T-cell lymphoma (PTCL), sponsored by Ruijin Hospital. Started Feb 2023; status: recruiting.
02
Drugs
selinexorazacitidineduvelisibtucidinostattislelizumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05675813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05675813.